



**Contacts:**

Dr. Israel Barken M.D.  
Medical Director  
Prostate Cancer Research and  
Educational Foundation (PC-REF)  
Tel (619) 461-8181  
[drbarken@pcref.org](mailto:drbarken@pcref.org)

Moshe Rogosnitzky  
Director of Research  
MedInsight Research Institute  
Tel: (302) 724-4531  
[mr@medinsight.org](mailto:mr@medinsight.org)

**New Study Shows Cough Medicine Effective Against Prostate Cancer**

---

**Dover, DE – February 15, 2007** – A presentation made at the 17th International Prostate Cancer Update Conference in Vail, Colorado, has shown noscopine to be effective against prostate cancer.

Noscopine, a non-addictive derivative of opium, has been used worldwide since the 1950's as an anti-cough medication. Noscopine was originally proposed as an anti-cancer agent in the early 1960's. However major studies of its broad anti-cancer effects were only done in recent years.

The study in prostate cancer is the result of ongoing collaboration between the Prostate Cancer Research and Educational Foundation (PC-REF) and MedInsight Research Institute.

Dr. Israel Barken, Founder and Medical Director of the Prostate Cancer Research and Educational Foundation (PC-REF) in San Diego, California, has used noscopine for treating prostate cancer for over a decade. Encouraged by successful results, Dr. Barken's foundation funded a laboratory study to confirm noscopine's effectiveness and mode of action in treating prostate cancer.

"In our study noscopine administered orally to animals had a tumor inhibition rate of 60%, and reduced metastasis by just over 65%. Incredibly, this was achieved with no toxicity thus demonstrating noscopine's potential not only as an effective anti-cancer agent, but a very safe one too", says Dr. Barken.

Dr. Barken is now planning on facilitating clinical trials with noscopine in patients suffering from prostate cancer. He has also pioneered a web-based patient tracking system, which allows for trials to be carried out with ease, and at substantially reduced costs. This will allow global participation of patients, which will drastically cut the time necessary to complete the study.

Moshe Rogosnitzky, Director of Research at MedInsight Research Institute, is very encouraged by the findings. "Noscopine has been used for cough-suppression for close to half a century. Recent discoveries are pointing to its effectiveness in treating a broad variety of cancers".

“Additionally, Iranian scientists have shown it very effective in treating strokes. It is a drug that is readily available, and in many countries can be bought without a prescription. Noscapine is a safe low-cost option that has the potential to successfully fight several life-threatening diseases”.

### **About Prostate Cancer Research and Educational Foundation (PC-REF)**

PC-REF, a 501(c)(3) non-profit public foundation based in San Diego, California. It was founded by Dr. Israel Barken in 1997. PC-REF focuses on patient empowerment, and provides financial support for innovative prostate cancer research projects. Its focus is on research ideas that can benefit today's patients. PC-REF's web site is [www.pcref.org](http://www.pcref.org).

### **About MedInsight Research Institute**

The MedInsight Research Institute is a US-based 501(c)3 non-profit public organization co-founded by Moshe Rogosnitzky of Israel and Dr. David Youlton of the UK. Its mission is to alleviate the suffering of those afflicted by life-threatening or chronic medical conditions. It does so by providing comprehensive scientific reviews of data regarding commercially-unsponsored medications, long-lost therapies, and specialized tests that enable the personalization of medical treatment. From July 2007 MedInsight will be making all its work public and freely available through its website.

NOTE TO EDITORS: For additional information, e-mail MedInsight Research Institute at [info@medinsight.org](mailto:info@medinsight.org).

###